<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519750</url>
  </required_header>
  <id_info>
    <org_study_id>2017-000997-13</org_study_id>
    <nct_id>NCT03519750</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers</brief_title>
  <official_title>Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Administration of Exogenous Melatonin in Healthy Female Volunteers: a Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dennis Bregner Zetner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RepoCeuticals ApS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will investigate the safety and pharmacokinetics of melatonin, when administered rectally,
      intravesically, vaginally and transdermally. We will recruit 10 healthy female volunteers.
      The volunteers will have melatonin administered over 5 days; intravenously, rectally,
      intravesically, vaginally and transdermally. The participants will be followed for 24-48
      hours with blood samples and questions about adverse events. There will be a wash-out between
      each session of a minimum of 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">February 21, 2019</completion_date>
  <primary_completion_date type="Actual">February 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each volunteer will have melatonin administered through all five routes of administration, and will have a wash-out of a minimum of 7 days between each administration.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of melatonin</measure>
    <time_frame>Baseline, 0 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours</time_frame>
    <description>Plasma concentration of melatonin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of melatonin</measure>
    <time_frame>Baseline, 0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 24 hours, 48 hours</time_frame>
    <description>Plasma concentration of melatonin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleepiness Scale</measure>
    <time_frame>0 minutes, once hourly for 8 hours, and again at 24 hours</time_frame>
    <description>Scale which evaluates tiredness of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple Reaction Time Test</measure>
    <time_frame>0 minutes, once hourly for 8 hours, and again at 24 hours</time_frame>
    <description>A simple reaction time test which measures the participants' reaction time; they are looking at a red lamp, and need to react when it changes to green.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Melatonin</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Intravenous melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration, making it possible to calculate bioavailability for other routes of administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rectal administration of melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravesical melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical administration of melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal administration of melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal administration of melatonin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 25 mg</intervention_name>
    <description>24-48 hour monitoring of plasma melatonin as well as adverse events.</description>
    <arm_group_label>Intravenous melatonin</arm_group_label>
    <arm_group_label>Intravesical melatonin</arm_group_label>
    <arm_group_label>Rectal melatonin</arm_group_label>
    <arm_group_label>Transdermal melatonin</arm_group_label>
    <arm_group_label>Vaginal melatonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy female

          -  20-40 years old

          -  BMI 18-30

        Exclusion criteria:

          -  Inability to understand Danish, written or spoken.

          -  Current use of melatonin or other hypnotics/sedatives

          -  Current pregnancy (a positive urine-HCG; the subjects will be tested prior to each
             study session)

          -  Breast feeding

          -  Current alcohol or drug abuse (defined as over 5 units of alcohol per day, or any
             usage of illegal drugs)

          -  Mental illness (defined as being in medical treatment)

          -  Serious comorbidity (American Society of Anesthesiologists (ASA) physical status 3-4)

          -  Participation in other clinical trials less than 1 month prior to current study

          -  Night-shift work within the last 14 days prior to study

          -  Planned night-shift work within the study period

          -  Known and diagnosed sleep-disorder (defined as being in current medical treatment)

          -  Plasma hemoglobin &lt;7.8 mmol/L (measured when screening participants)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>They need to be female, in order to receive vaginal administration of melatonin</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis B Zetner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Perioperative Optimization, Department of Surgery, Herlev Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dennis Bregner Zetner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03519750/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

